Table I. Time until redosing in days... | Rockefeller University Press

Table I.

Time until redosing in days after different doses and routes of administration of canakinumab

Patient	10 mg/kg i.v.	1 mg/kg i.v.	First 150 mg s.c.	Second 150 mg s.c.	Third 150 mg s.c.	Fourth 150 mg s.c.	Fifth 150 mg s.c.	Sixth 150 mg s.c.
1	168	90	120	119	112	133	113^a	n.a.
2	189	91	98	133	126	132	90^a	n.a.
3	203	77	133	140	132	134^a	n.a.	n.a.
4	182	98	118	141	132	127^a	n.a.	n.a.
5	n.a.	n.a.	187	156	161^a	n.a.	n.a.	n.a.
6	n.a.	n.a.	91	84	98	78	55	85
7	n.a.	n.a.	168	230^a	n.a.	n.a.	n.a.	n.a.

Patient	10 mg/kg i.v.	1 mg/kg i.v.	First 150 mg s.c.	Second 150 mg s.c.	Third 150 mg s.c.	Fourth 150 mg s.c.	Fifth 150 mg s.c.	Sixth 150 mg s.c.
1	168	90	120	119	112	133	113a	n.a.
2	189	91	98	133	126	132	90a	n.a.
3	203	77	133	140	132	134a	n.a.	n.a.
4	182	98	118	141	132	127a	n.a.	n.a.
5	n.a.	n.a.	187	156	161a	n.a.	n.a.	n.a.
6	n.a.	n.a.	91	84	98	78	55	85
7	n.a.	n.a.	168	230a	n.a.	n.a.	n.a.	n.a.

Patients 1–4 were initially treated with 10 mg/kg and 1 mg/kg i.v. and subsequently with fixed doses of 150 mg s.c. Patients 5–7 did not receive i.v. dosing but received fixed doses of 150 mg s.c. Because of difficulties being compliant with study visit requests, patient 6 withdrew consent after the sixth dose of 150 mg canakinumab s.c. The patient was subsequently treated with anakinra. n.a., not applicable.

After this cycle, patients were rolled over into the subsequent study, in which they were treated with a fixed dosing regimen of 150 mg s.c. every 8 wk.

[ViewLarge]

Gift article access

Gift article access

Gift article access

Gift article access

Sharing Unavailable